C.M. Bidwell & Associates’s Biogen BIIB Stock Holding History

C.M. Bidwell & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-348	Closed	-$99.1K	–	526
2023 Q2	$99.1K	Sell	348 -418	-55%	-$124K	0.07%	242
2023 Q1	$213K	Sell	766 -40	-5%	-$11.1K	0.16%	112
2022 Q4	$223K	Hold	806	–	–	0.18%	108
2022 Q3	$215K	Buy	+806	New	+$171K	0.18%	101
2020 Q3	–	Sell	-370	Closed	-$99K	–	460
2020 Q2	$99K	Sell	370 -385	-51%	-$116K	0.09%	210
2020 Q1	$239K	Sell	755 -993	-57%	-$301K	0.25%	102
2019 Q4	$519K	Sell	1,748 -46	-3%	-$12.8K	0.47%	54
2019 Q3	$418K	Buy	+1,794	New	+$418K	0.41%	59
2019 Q2	–	Sell	-1,190	Closed	-$281K	–	399
2019 Q1	$281K	Buy	+1,190	New	+$375K	0.28%	99
2015 Q2	–	Sell	-9,200	Closed	-$3.88M	–	217
2015 Q1	$3.88M	Buy	+9,200	New	+$3.63M	0.86%	55

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

C.M. Bidwell & Associates's BIIB Position: Q3 2023 in Review

C.M. Bidwell & Associates sold out of Biogen (BIIB) in Q3 2023, closing a stake of 348 shares — an estimated $99.1K sold.

C.M. Bidwell & Associates first reported a position in BIIB in Q1 2015 and held it in 10 quarters. The position peaked at $3.88M in Q1 2015. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

C.M. Bidwell & Associates reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 348 Biogen shares in Q3 2023, an estimated $99.1K.
C.M. Bidwell & Associates first reported a position in Biogen in Q1 2015 and held it in 10 quarters.
C.M. Bidwell & Associates's Biogen position peaked at $3.88M in Q1 2015.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2023, filed 13 Nov 2023.